J Korean Neurosurg Soc.  2019 Sep;62(5):493-501. 10.3340/jkns.2018.0222.

Human Induced Pluripotent Stem Cells: Clinical Significance and Applications in Neurologic Diseases

• Chang EA
• Jin SW
• Nam MH
• Kim SD

• KMID: 2457939
• DOI: http://doi.org/10.3340/jkns.2018.0222

Abstract

The generation of human induced pluripotent stem cells (iPSCs) from somatic cells using gene transfer opens new areas for precision medicine with personalized cell therapy and encourages the discovery of essential platforms for targeted drug development. iPSCs retain the genome of the donor, may regenerate indefinitely, and undergo differentiation into virtually any cell type of interest using a range of published protocols. There has been enormous interest among researchers regarding the application of iPSC technology to regenerative medicine and human disease modeling, in particular, modeling of neurologic diseases using patient-specific iPSCs. For instance, Parkinson's disease, Alzheimer's disease, and spinal cord injuries may be treated with iPSC therapy or replacement tissues obtained from iPSCs. In this review, we discuss the work so far on generation and characterization of iPSCs and focus on recent advances in the use of human iPSCs in clinical setting.

Keyword

Cell-based therapy; Induced pluripotent stem cells; Precision medicine

MeSH Terms

Cell- and Tissue-Based Therapy
Genome
Humans*
Induced Pluripotent Stem Cells*
Precision Medicine
Regenerative Medicine
Spinal Cord Injuries
Tissue Donors

Figure

• 

  Fig. 1. Isolation and characterization of pluripotent stem cells. ESC : embryonic stem cell, ICM : inner cell mass, iPSC : induced pluripotent stem cell, ASC : adult stem cell, CNS : central nervous system.

• 

  Fig. 2. Generation and applications of iPSCs from somatic cells. iPSCs can be applied in the field of clinical research for 1) patient-specific cell therapy, 2) drug screening, and 3) disease modeling. iPSC : induced pluripotent stem cell, Oct4 : octamer-binding transcription factor 4, Klf4 : Krüppel-like factor 4, Sox2 : SRY-box containing gene 2, c-Myc : cytoplasmic Myc gene.

• 

  Fig. 3. Safety of cell reprogramming technologies.

Reference

References

1. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 94:278–293.e9. 2017.

2. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol. 27:213–214. 2009.

3. Assawachananont J, Mandai M, Okamoto S, Yamada C, Eiraku M, Yonemura S, et al. Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Reports. 2:662–674. 2014.

4. Bejleri D, Streeter BW, Nachlas ALY, Brown ME, Gaetani R, Christman KL, et al. A bioprinted cardiac patch composed of cardiac-specific extracellular matrix and progenitor cells for heart repair. Adv Heathc Mater. 7:e1800672. 2018.

5. Charron D, Suberbielle-Boissel C, Al-Daccak R. Immunogenicity and allogenicity: a challenge of stem cell therapy. J Cardiovasc Transl Res. 2:130–138. 2009.

6. Chen KG, Mallon BS, McKay RD, Robey PG. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell. 14:13–26. 2014.

7. Chen N, Kamath S, Newcomb J, Hudson J, Garbuzova-Davis S, Bickford P, et al. Trophic factor induction of human umbilical cord blood cells in vitro and in vivo. J Neural Eng. 4:130–145. 2007.

8. Cohen MA, Itsykson P, Reubinoff BE. Neural differentiation of human ES cells. Curr Protoc Cell Biol Chapter. 23:Unit 23.7. 2007.

9. Cramer AO, MacLaren RE. Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases. Curr Gene Ther. 13:139–151. 2013.

10. Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med. 23:878–884. 2017.

11. Dhawan A, Kennedy PM, Rizk EB, Ozbolat IT. Three-dimensional bioprinting for bone and cartilage restoration in orthopaedic surgery. J Am Acad Orthop Surg. 27:e215–e226. 2019.

12. Drukker M, Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 22:136–141. 2004.

13. Duncan ID. Oligodendrocytes and stem cell transplantation: their potential in the treatment of leukoencephalopathies. J Inherit Metab Dis. 28:357–368. 2005.

14. Enciso J, Mayani H, Mendoza L, Pelayo R. Modeling the pro-inflammatory tumor microenvironment in acute lymphoblastic leukemia predicts a breakdown of hematopoietic-mesenchymal communication networks. Front Physiol. 7:349. 2016.

15. Fajardo-Orduña GR, Mayani H, Montesinos JJ. Hematopoietic support capacity of mesenchymal stem cells: biology and clinical potential. Arch Med Res. 46:589–596. 2015.

16. Fehlings MG, Vawda R. Cellular treatments for spinal cord injury: the time is right for clinical trials. Neurotherapeutics. 8:704–720. 2011.

17. Flores-Guzmán P, Fernández-Sánchez V, Mayani H. Concise review: ex vivo expansion of cord blood-derived hematopoietic stem and progenitor cells: basic principles, experimental approaches, and impact in regenerative medicine. Stem Cells Transl Med. 2:830–838. 2013.

18. Fluckiger AC, Dehay C, Savatier P. Embryonic stem cells and cell replacement therapies in the nervous system. Med Sci (Paris). 19:699–708. 2003.

19. Freude K, Pires C, Hyttel P, Hall VJ. Induced pluripotent stem cells derived from Alzheimer’s disease patients: the promise, the hope and the path ahead. J Clin Med. 3:1402–1436. 2014.

20. Gensel JC, Donnelly DJ, Popovich PG. Spinal cord injury therapies in humans: an overview of current clinical trials and their potential effects on intrinsic CNS macrophages. Expert Opin Ther Targets. 15:505–518. 2011.

21. Goh PA, Caxaria S, Casper C, Rosales C, Warner TT, Coffey PJ, et al. A systematic evaluation of integration free reprogramming methods for deriving clinically relevant patient specific induced pluripotent stem (iPS) cells. PLoS One. 8:e81622. 2013.

22. Gu BK, Choi DJ, Park SJ, Kim YJ, Kim CH. 3D bioprinting technologies for tissue engineering applications. Adv Exp Med Biol. 1078:15–28. 2018.

23. Gu Q, Tomaskovic-Crook E, Wallace GG, Crook JM. 3D Bioprinting human induced pluripotent stem cell constructs for in situ cell proliferation and successive multilineage differentiation. Adv Heathc Mater. 6:1700175. 2017.

24. Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell. 16:269–274. 2015.

25. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell. 143:508–525. 2010.

26. Ho BX, Pek NMQ, Soh BS. Disease modeling using 3D organoids derived from human induced pluripotent stem cells. Int J Mol Sci. 19:936. 2018.

27. Isobe Y, Koyama N, Nakao K, Osawa K, Ikeno M, Yamanaka S, et al. Comparison of human mesenchymal stem cells derived from bone marrow, synovial fluid, adult dental pulp, and exfoliated deciduous tooth pulp. Int J Oral Maxillofac Surg. 45:124–131. 2016.

28. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 482:216–220. 2012.

29. Kawagoe S, Higuchi T, Otaka M, Shimada Y, Kobayashi H, Ida H, et al. Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). Mol Genet Metab. 109:386–389. 2013.

30. Kfoury Y, Scadden DT. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 16:239–253. 2015.

31. Kim JH, Kim HW, Cha KJ, Han J, Jang YJ, Kim DS, et al. Nanotopography promotes pancreatic differentiation of human embryonic stem cells and induced pluripotent stem cells. ACS Nano. 10:3342–3355. 2016.

32. Kim SJ, Park J, Byun H, Park YW, Major LG, Lee DY, et al. Hydrogels with an embossed surface: an all-in-one platform for mass production and culture of human adipose-derived stem cell spheroids. Biomaterials. 188:198–212. 2019.

33. Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest. 120:51–59. 2010.

34. Kobayashi Y, Okada Y, Itakura G, Iwah H, Nishimura S, Yasuda A, et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One. 7:e52787. 2012.

35. Konagaya S, Ando T, Yamauchi T, Suemori H, Iwata H. Long-term maintenance of human induced pluripotent stem cells by automated cell culture system. Sci Rep. 5:16647. 2015.

36. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 12:487–496. 2013.

37. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 501:373–379. 2013.

38. Levison SW, Druckman SK, Young GM, Basu A. Neural stem cells in the subventricular zone are a source of astrocytes and oligodendrocytes, but not microglia. Dev Neurosci. 25:184–196. 2003.

39. Li W, Li K, Wei W, Ding S. Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell. 13:270–283. 2013.

40. Liu C, Oikonomopoulos A, Sayed N, Wu JC. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 145:dev156166. 2018.

41. Liu K, Yu C, Xie M, Li K, Ding S. Chemical modulation of cell fate in stem cell therapeutics and regenerative medicine. Cell Chem Biol. 23:893–916. 2016.

42. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 1:55–70. 2007.

43. Marx V. Stem cells: disease models that show and tell. Nat Methods. 12:111–114. 2015.

44. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 25:1177–1181. 2007.

45. Melton D. ‘Stemness’: Definitions, Criteria, and Standards. In : Lanza R, Atala A, editors. Essentials of Stem Cell Biology. . London: Elsevier;2014. p. 7–17.

46. Messina DJ, Alder L, Tresco PA. Comparison of pure and mixed populations of human fetal-derived neural progenitors transplanted into intact adult rat brain. Exp Neurol. 184:816–829. 2003.

47. Montesinos JJ, Mora-García Mde L, Mayani H, Flores-Figueroa E, García-Rocha R, Fajardo-Orduña GR, et al. In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev. 22:2508–2519. 2013.

48. Montgomery A, Wong A, Gabers N, Willerth SM. Engineering personalized neural tissue by combining induced pluripotent stem cells with fibrin scaffolds. Biomater Sci. 3:401–413. 2015.

49. Nakamura M, Okano H. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res. 23:70–80. 2013.

50. Narsinh KH, Jia F, Robbins RC, Kay MA, Longaker MT, Wu JC. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc. 6:78–88. 2011.

51. Nestor MW, Noggle SA. Standardization of human stem cell pluripotency using bioinformatics. Stem Cell Res Ther. 4:37. 2013.

52. Nori S, Okada Y, Yasuda A, Tsuji O, Takashashi Y, Kobayashi Y, et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A. 108:16825–16830. 2011.

53. Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 112:523–533. 2013.

54. Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 5:418–428. 2010.

55. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 448:313–317. 2007.

56. Ong CS, Fukunishi T, Nashed A, Blazeski A, Zhang H, Hardy S, et al. Creation of cardiac tissue exhibiting mechanical integration of spheroids using 3D bioprinting. J Vis Exp. 125:e55438. 2017.

57. Ong CS, Yesantharao P, Huang CY, Mattson G, Boktor J, Fukunishi T, et al. 3D bioprinting using stem cells. Pediatr Res. 83:223–231. 2018.

58. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 451:141–146. 2008.

59. Park KS, Cha KJ, Han IB, Shin DA, Cho DW, Lee SH, et al. Mass-producible nano-featured polystyrene surfaces for regulating the differentiation of human adipose-derived stem cells. Macromol Biosci. 12:1480–1489. 2012.

60. Park S, Kim D, Park S, Kim S, Lee D, Kim W, et al. Nanopatterned scaffolds for neural tissue engineering and regenerative medicine. Adv Exp Med Biol. 1078:421–443. 2018.

61. Piao Y, Hung SS, Lim SY, Wong RC, Ko MS. Efficient generation of integration-free human induced pluripotent stem cells from keratinocytes by simple transfection of episomal vectors. Stem Cells Transl Med. 3:787–791. 2014.

62. Poon A, Li T, Pires C, Nielsen TT, Nielsen JE, Holst B, et al. Derivation of induced pluripotent stem cells from a familial Alzheimer’s disease patient carrying the L282F mutation in presenilin 1. Stem Cell Res. 17:470–473. 2016.

63. Poon A, Zhang Y, Chandrasekaran A, Phanthong P, Schmid B, Nielsen TT, et al. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: possibilities and challenges. N Biotechnol. 39(Pt B):190–198. 2017.

64. Poulsen FR, Meyer M, Rasmussen JZ. Generation of new nerve cells in the adult human brain. Ugeskr Laeger. 165:1443–1447. 2003.

65. Qian X, Nguyen HN, Song MM, Hadiono C, Ogden SC, Hammack C, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell. 165:1238–1254. 2016.

66. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 481:295–305. 2012.

67. Rossi SL, Nistor G, Wyatt T, Yin HZ, Poole AJ, Weiss JH, et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS One. 5:e11852. 2010.

68. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med. 4:380–395. 2012.

69. Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis. 62:381–386. 2014.

70. Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, et al. Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia. PLoS One. 11:e0164795. 2016.

71. Satpathy A, Datta P, Wu Y, Ayan B, Bayram E, Ozbolat IT. Developments with 3D bioprinting for novel drug discovery. Expert Opin Drug Discov. 13:1115–1129. 2018.

72. Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 379:713–720. 2012.

73. Sharp J, Frame J, Siegenthaler M, Nistor G, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells. 28:152–163. 2010.

74. Soria-Valles C, López-Otín C. iPSCs: on the road to reprogramming aging. Trends Mol Med. 22:713–724. 2016.

75. Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol. 28:989–990. 2010.

76. Takahashi K, Tanabe K, Ohnuki M, Naritta M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861–872. 2007.

77. Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 17:183–193. 2016.

78. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. 2006.

79. Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell. 18:587–590. 2016.

80. Telpalo-Carpio S, Aguilar-Yañez J, Gonzalez-Garza M, Cruz-Vega D, Moreno-Cuevas J. iPS cells generation: an overview of techniques and methods. J Stem Cells Regen Med. 9:2–8. 2013.

81. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 282:1145–1147. 1998.

82. Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 13:382–384. 2013.

83. Wang X, Dai X, Zhang X, Ma C, Li X, Xu T, et al. 3D bioprinted glioma cell-laden scaffolds enriching glioma stem cells via epithelial-mesenchymal transition. J Biomed Mater Res A. 107:383–391. 2019.

84. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 7:618–630. 2010.

85. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet. 20:4530–4539. 2011.

86. Yamanaka S, Li J, Kania G, Elliott S, Wersto RP, Van Eyk J, et al. Pluripotency of embryonic stem cells. Cell Tissue Res. 331:5–22. 2008.

87. Yang W, Mills JA, Sullivan S, Liu Y, French DL, Gadue P. iPSC Reprogramming from Human Peripheral Blood Using Sendai Virus Mediated Gene Transfer. Cambridge: StemBook;2008.

88. Yasuda A, Tsuji O, Shibata S, Nori S, Takano M, Kobayashi Y, et al. Significance of remyelination by neural stem/progenitor cells transplanted into the injured spinal cord. Stem Cells. 29:1983–1994. 2011.

89. Ye H, Wang Q. Efficient generation of non-integration and feeder-free induced pluripotent stem cells from human peripheral blood cells by Sendai virus. Cell Physiol Biochem. 50:1318–1331. 2018.

90. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol. 50:327–332. 2011.

91. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324:797–801. 2009.

92. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 318:1917–1920. 2007.

93. Zhang SC, Li XJ, Johnson MA, Pankratz MT. Human embryonic stem cells for brain repair? Philos Trans R Soc Lond B Biol Sci. 363:87–99. 2008.

94. Zhang Y, Schmid B, Nikolaisen NK, Rasmussen MA, Aldana BI, Agger M, et al. Patient iPSC-derived neurons for disease modeling of frontotemporal dementia with mutation in CHMP2B. Stem Cell Reports. 8:648–658. 2017.

95. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 4:381–384. 2009.

96. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature. 455:627–632. 2008.

97. Zhou Q, Melton DA. Extreme makeover: converting one cell into another. Cell Stem Cell. 3:382–388. 2008.

98. Zhou Q, Melton DA. Pathways to new beta cells. Cold Spring Harb Symp Quant Biol. 73:175–181. 2008.

99. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 27:2667–2674. 2009.